...Sure. First off, thanks, Kelly, for having me. It's good to be here, and thank you all for attending to hear our story and to share where we are in our stage of development. As you said, we are focused on treating hyperinsulinism. And specifically, we have an antibody that is designed to serve as a universal treatment for all forms of hyperinsulinism. When we think about hyperinsulinism, it's not just the overstimulation of the insulin receptor, but it is a dangerous hypoglycemia that's a byproduct of that condition. And one area starts at birth, there's congenital forms of hyperinsulinism. So these are children based on a set of known and still unknown genetic defects where they overproduce insulin and overstimulate the insulin receptor, causing the body to uptake glucose excessively, which then creates the dangerous hypoglycemia. From that to the other side, you can have something similar happen with tumors where a tumor can overproduce insulin or insulin-like substances, overstimulating...
